Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: TheStreet.com Ratings
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sorrento Therapeutics Inc Enters Into Definitive Agreement To Acquire San Diego-Based Concortis Biosystems Corp


Thursday, 14 Nov 2013 07:00am EST 

Sorrento Therapeutics Inc announced the entry into a definitive agreement to acquire San Diego-based Concortis Biosystems Corp in a deal that provides Sorrento with a comprehensive technology platform for generation of antibody drug conjugates (ADC). Under the terms of the agreement dated November 11, 2013, upon closing, Sorrento will issue an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. Financial terms of the transaction were not disclosed.